Objective: To clarify the impact of prostate-specific antigen screening on surgical outcomes of prostate cancer. Methods: Patients who underwent radical prostatectomy were divided into two groups according to prostate-specific antigen testing opportunity (group 1, prostatespecific antigen screening; group 2, non-prostate-specific antigen screening). Perioperative clinical characteristics were compared using the Wilcoxon rank-sum and v 2 -tests. Cox proportional hazards models were used to identify independent predictors of postoperative biochemical recurrence-free survival. Results: In total, 798 patients (63.2%) and 464 patients (36.8%) were categorized into groups 1 and 2, respectively. Group 2 patients were more likely to have a higher prostate-specific antigen level and age at diagnosis and larger prostate volume. Clinical T stage, percentage of positive cores and pathological Gleason score did not differ between the groups. The 5-year biochemical recurrence-free survival rate was 83.9% for group 1 and 71.0% for group 2 (P < 0.001). On multivariate analysis, prostate-specific antigen testing opportunity (hazard ratio 2.530; P < 0.001) was an independent predictive factor for biochemical recurrence after surgery, as well as pathological T stage, pathological Gleason score, positive surgical margin and lymphovascular invasion. Additional analyses showed that prostate-specific antigen screening had a greater impact on biochemical recurrence in a younger patients, patients with a high prostate-specific antigen level, large prostate volume and D'Amico high risk, and patients meeting the exclusion criteria of the Prostate Cancer Research International Active Surveillance study. Conclusions: Detection by screening results in favorable outcomes after surgery. Prostate-specific antigen screening might contribute to reducing biochemical recurrence in patients with localized prostate cancer.
Introduction
The incidence and mortality rates of prostate cancer in Japan are low compared to those in Western countries. 1, 2 Some groups have reported that although Japanese men have a lower risk of prostate cancer, their pathological features reflect greater severity than patients in North America. 3, 4 A study including 108 academic and community practices throughout Japan found that preoperative serum PSA levels and Gleason scores were higher in a Japanese cohort compared with those in an American cohort. 3 Similarly, several previous reports of Japanese cohorts have reported poorer prognosis after RP compared with North American or European cohorts. [5] [6] [7] It has been reported that the rate of PSA screening in Japan is much lower than that in European counties. 8 Thus, we hypothesized that poorer prognosis after RP in Japan might be caused by the lower rate of PSA screening. Therefore, the present study aimed to investigate whether PSA testing opportunity is related to prostate cancer prognosis in patients who underwent RP. exclusion criteria of the present study in Figure 1 , and a retrospective review was carried out of the remaining 1262 patients' medical records. In the present study, patients were divided into two groups according to their PSA testing opportunity. Group 1 was defined as patients who underwent PSA screening at a medical checkup without reporting symptoms. Group 2 was defined as patients who underwent PSA testing at a clinical urological practice for any reason. We evaluated specimens according to WHO classification 9 and the General Rules for Clinical and Pathological Studies on Prostate Cancer in Japan, 4th edition. 10 For patients who were referred from other hospitals, all biopsy specimens acquired at the other hospitals were re-examined at our institution. Although some small surgical modifications were made during the study period, RARP was carried out using the intraperitoneal six-port technique in most cases, whereas most nerve-sparing procedures were carried out using the interfascial technique. An extended lymph node dissection was carried out in high-risk patients. A total of 11 attending surgeons carried out RARP in the present study. Of the 11 surgeons, two carried out >500 surgeries during the study period. In addition, many surgical fellows carried out RARP under expert guidance. A positive surgical margin was defined as tumor extension into the inked surface of the resected specimen. BCR was defined as two consecutive increased PSA measurements of ≥0.2 ng/mL postoperatively. 11 Patients who never achieved a PSA level <0.2 ng/mL after RP were considered to have immediate BCR at the operative date.
We used a Wilcoxon rank-sum test to compare continuous variables and v 2 -tests to compare categorical variables between groups. Statistical analysis of BCR-FS was carried out using the Kaplan-Meier method. BCR-FS was compared between groups using the log-rank test. In addition, univariate and multivariate Cox proportional hazards regression analyses were used to evaluate the prognostic significance for BCR. A P <0.05 was considered statistically significant. Additionally, we analyzed the data based on D'Amico risk stratification and the PRIAS study criteria in 2012 to assess patients with potentially insignificant prostate cancer. All statistical analyses were carried out using Stata software (version 14.0; StataCorp, College Station, TX, USA). Total 1262 patients were eligible for the present study Fig. 1 Flow chart of the present study.
Results
In the present study, 798 patients underwent PSA screening during a medical checkup (group 1), and 464 patients underwent PSA testing at a clinical urological practice (group 2). In group 2, 303 patients had a PSA test for lower urinary tract symptoms, 28 patients for hematuria, nine patients for hematospermia, 14 patients for possible prostatitis, 10 patients on scrotal pain, five patients on abnormal bone imaging, five patients on abnormal rectal examination and one patient due to loss of bodyweight. A total of 89 patients had a PSA test during follow up for another disease not involving the prostate. Table 1 shows the preoperative patient characteristics in each group. Patients in group 2 were more likely to have a higher PSA (P < 0.001), higher age (P < 0.001) at diagnosis and a larger prostate volume (P < 0.001), whereas clinical T stage, the number of positive cores, percentage of positive cores and biopsy Gleason score did not differ between the groups. Patients in group 2 had significantly higher rates of positive lymphovascular invasion compared with patients in group 1, although pathological T stage, pathological Gleason score, surgical margin status, perineural invasion and lymph node involvement did not differ between the groups ( Table 1) .
The median follow-up period after surgery in the total cohort of 1262 patients was 24.3 months, ranging from 1.5 to 118 months, and 166 patients (13.2%) experienced BCR during the follow-up period. The 1-, 3-and 5-year BCR-FS rates for the entire cohort were 92.5%, 85.4% and 79.4%, respectively. The BCR-FS rate at 5 years for group 1 was 83.9%, compared with 71.0% in group 2 (P < 0.001, Fig. 2 analysis, PSA testing opportunity (HR 2.530; P < 0.001) was an independent predictive factor for BCR after surgery, as well as pathological T stage (HR 1.442; P < 0.001), pathological Gleason score (HR 1.690; P < 0.001), positive surgical margin (HR 2.322; P < 0.001) and lymphovascular invasion (HR 1.524; P = 0.018). We further analyzed the significance of PSA screening based on D'Amico risk stratification and PRIAS study criteria. When we analyzed only patients at low D'Amico risk or those included in the PRIAS study, PSA screening did not significantly impact BCR (Table 3 ). In addition, as some variables that significantly differed between groups might influence BCR, we carried out additional analyses dividing patients according to age (age <65 years, ≥65 years), PSA level (PSA <7 ng/mL, ≥7 ng/ mL) and prostate volume (volume <30 ml, ≥30 mL) as sensitive analyses. The multivariate Cox model for BCR-FS adjusted for the same covariates showed that PSA testing opportunity was an independent predictor for BCR in all subdivided groups, consistent with the results of the primary analysis (Table 3) . These results showed that PSA screening had a greater impact in patients who were younger (age <65 years, HR 2.72; P < 0.001), had a higher PSA level (≥7 ng/mL, HR 2.55; P < 0.001) and had a greater prostate volume (≥30 mL, HR 3.11; P < 0.001). In addition, it is interesting that PSA screening is particularly effective in patients with a high D'Amico risk (HR 2.74; P < 0.001) and patients meeting the PRIAS study exclusion criteria (HR 2.65; P < 0.001). Figure 3 shows that the BCR-FS curves divided into subgroups according to PSA testing opportunity and D'Amico risk stratification, PRIAS study criteria, age, PSA level or prostate volume.
Discussion
Many studies had developed BCR-predicting RP models, such as D'Amico risk stratification, CAPRA-s and Stephenson nomogram, but did not mention PSA test opportunities. 12-14 A prostate cancer in patients who were referred because of an elevated PSA at an annual medical checkup and so on is potentially different from a cancer in patients diagnosed at an outpatient clinic in the evaluation for other reasons. Therefore, it is necessary to investigate the effect of PSA screening on prostate cancer characteristics. In the present study, we confirmed that pathological features of cancer and BCR-FS were more favorable in patients identified through PSA screening than patients who underwent PSA testing at a urology clinic. This finding is unsurprising given the previous reports that PSA-based screening significantly reduced mortality from prostate cancer. 15, 16 Thus, the present findings show that PSA screening contributes to early detection and ultimately improves the BCR-FS rate after RP, even in patients with localized prostate cancer.
There are several possible reasons why the patients detected at a urology clinic are more likely to have a poor prognosis than those detected at PSA screening. In group 2, patients had a variety of reasons for visiting an outpatient clinic, including lower urinary obstructive symptoms. Indeed, some previous studies have shown that the presence of Fig. 2 Patients divided according to PSA testing opportunity. The BCR-FS rate in patients who underwent PSA testing during a medical checkup was significantly higher than that in patients who underwent PSA testing offered during a clinical examination. Total n = 1262.
symptoms indicates more advanced prostate cancer, which could explain symptomatic patients' poorer outcomes. [17] [18] [19] [20] [21] In an investigation of 2154 patients who had radical prostatectomy and were followed for a median of 10.2 years after surgery, Ta et al. found that, in addition to Gleason score and pathological stage, symptomatic presentation was associated with prostate cancer-specific mortality. 17 Beckman et al. recently reported that in a cohort of 4841 patients with clinically localized prostate cancer, among the patients treated with RP, those with symptoms had poorer survival than asymptomatic patients. 18 In the present study, age, PSA level and prostate volume were significantly different among groups. The results of this study suggest that PSA screening allows the diagnosis of prostate cancer in patients who are younger and have lower PSA levels. Considering these results, it is possible that PSA screening enables the diagnosis and treatment of younger patients having cancer at an earlier stage. Although the effect of PSA screening was limited when prostate cancer could be identified in the cases of low D'Amico risk or satisfied PRIAS inclusion criteria, PSA screening was highly effective in patients at a high D'Amico risk and/or PRIAS exclusion patients who required aggressive therapy. Furthermore, the effect of PSA screening was higher in a younger patients, which is considered very important to decide treatment strategy. Carlsson et al. reported previously that PSA screening of men aged in their early 50s carried a more than twofold higher risk of prostate cancer diagnosis compared with unscreened men, but resulted in a substantial decrease in the risk of metastases and prostate cancer death. 22 The present study might also support this finding. Therefore, PSA screening for younger men with lower PSA level appears to be important in terms of the early detection and treatment of prostate cancer.
A previous study showed that the Asian population had a relatively high rate of advanced prostate cancer at detection, which was mainly attributable to the lack of mass screening. 23 Another previous report suggested that formal PSA screening programs might be more effective for improving prostate cancer mortality than unorganized screening. 24 Although the Japanese Urological Association recommended PSA screening, a population-based PSA screening program is not currently in place in Japan. 25 Therefore, Japanese men aged in their 50s prefer to avoid PSA testing because of the low incidence of prostate cancer and lack of concern toward it. As the USPSTF discouraged PSA-based prostate cancer screening in 2012, the incidence of early-stage prostate cancer and rates of PSA screening have declined. 26, 27 These results suggest that overdiagnosis might be reduced by decreasing the rate of PSA screening. However, other reports have shown that the incidence of aggressive prostate cancer has increased since USPSTF recommendations. 28, 29 Many controversies about screening revolve around the PLCO Cancer Screening Trial, which randomly assigned men to PSA screening or control. However, there was considerable contamination of the control group in that study. That is, according to the report, approximately 50% of men in the control group underwent at least one PSA test during the study. Shoag et al. reassessed PSA screening in the PLCO Cancer Screening Trial and commented that the proportion of control participants who reported having undergone at least one PSA test before or during the trial was close to 90%. 30 Therefore, we should reason that the reliability of the evidence in the PLCO Cancer Screening Trial in regard to PSA screening is lower than indicated. Several reports commented that highgrade or advanced prostate cancer was often detected after the USPSTF discouraged the use of PSA screening in 2012. 28, 29 Therefore, the USPSTF changed the grade definition of PSA screening from D to C in 2017, although it recommends that clinicians inform men aged 55-69 years about the potential benefits and harms of PSA screening for prostate cancer (https://screeningforprostatecancer.org/ and https://www.uspreventiveservicestaskforce.org/Page/Document/ RecommendationStatementDraft/prostate-cancer-screening1).
Although it is necessary to await the results of further investigation, PSA screening might have contributed to improving prostate cancer prognosis, in contrast to the USPSTF recommendations. Given the difference between high prevalence and low mortality rate of prostate cancer in Japan, the potential effectiveness of PSA screening in Japan is much more controversial. Although population-based PSA screening programs carry a risk of overdiagnosis and overtreatment for patients with low-risk prostate cancer, oncological outcomes are expected to improve as PSA screening becomes more widespread in Japan, as in the USA and European countries. The present study had several limitations. It was a retrospective study that involved the analysis of data collected from patients who underwent RP at a single institution. Prostate cancer patients can choose from other treatment options, such as active surveillance, brachytherapy, radiation therapy and androgen deprivation therapy. In the present cohort, we could survey only patients who underwent RARP. Therefore, the population in the present study did not represent the entire population of patients with prostate cancer. Second, as the PSA screening prevalence in Japan is much lower than European countries, the population of prostate cancer in the present study who underwent PSA screening still might be different from actual prostate cancer patients in those countries. Third, we did not have data regarding possible clinically insignificant cancer, and consequently we could not evaluate the possible disadvantages of PSA screening in the present study. However, just 7% of patients had a completely confined cancer with no poorly differentiated area (Gleason grade 4 or 5), and among these patients, only a small percentage had a focal cancer. Therefore, we estimate that a very small number of the patients might have had pathologically insignificant cancer. Finally, surgical technique bias could be involved in the present study. In our facility, many young and inexperienced surgeons started to carry out RARP during the study period. In addition, many surgical fellows carried out RARP under expert guidance. Therefore, we can presume that those surgical technique biases about the learning curve did not influence the outcome. Although it is necessary to carefully evaluate the presence of clinically insignificant cancers, we believe that the advantages of PSA screening might overcome the disadvantages at present in Japan. However, we need careful and further examination, as PSA screening would be beneficial for improving prostate cancer mortality. The present study showed that the PSA testing opportunity impacted cancer characteristics in patients with localized prostate cancer. Patients who were treated with RP after diagnosis based on a PSA screening test tended to have cancers in an early phase. Even among patients in the same PSA range, such as <7 ng/mL, those identified through PSA screening had a superior BCR-FS to those with PSA measured at a urology clinic. PSA testing opportunity was also a significant predictor of BCR-FS after controlling for pathological T stage, Gleason score and positive surgical margin. These results show the importance of early prostate cancer detection through PSA screening.
